CORCEPT THERAPEUTICS INC Cost of Revenue
CORCEPT THERAPEUTICS INC (CORT) reported Cost of Revenue of $1.36 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-10.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2016-03-10
- CORCEPT THERAPEUTICS INC cost of revenue for the quarter ending 2015-12-31 was $364.00K, a 41.09% increase year-over-year.
- CORCEPT THERAPEUTICS INC cost of revenue for the quarter ending 2015-09-30 was $256.00K, a 8.94% increase year-over-year.
- CORCEPT THERAPEUTICS INC cost of revenue for the quarter ending 2015-06-30 was $439.00K, a 104.19% increase year-over-year.
- CORCEPT THERAPEUTICS INC cost of revenue for the quarter ending 2015-03-31 was $302.00K, a 73.56% increase year-over-year.
- CORCEPT THERAPEUTICS INC cost of revenue for fiscal 2015 was $1.36M, a 54.31% increase from fiscal 2014.
- CORCEPT THERAPEUTICS INC cost of revenue for fiscal 2014 was $882.00K, a 516.78% increase from fiscal 2013.
- CORCEPT THERAPEUTICS INC cost of revenue for fiscal 2013 was $143.00K, a 57.14% increase from fiscal 2012.
- CORCEPT THERAPEUTICS INC cost of revenue for fiscal 2012 was $91.00K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2015-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $620.00K derived: sum of 2 quarters · filed 2016-03-10 | $1.06M derived: sum of 3 quarters · filed 2016-03-10 | $1.36M 10-K · filed 2016-03-10 |
| 2015-09-30 | $256.00K 10-Q · filed 2015-11-06 | $695.00K derived: sum of 2 quarters · filed 2015-11-06 | $997.00K 10-Q · filed 2015-11-06 | $1.25M derived: sum of 4 quarters · filed 2016-03-10 |
| 2015-06-30 | $439.00K 10-Q · filed 2015-08-07 | $741.00K 10-Q · filed 2015-08-07 | $999.00K derived: sum of 3 quarters · filed 2016-03-10 | $1.23M derived: sum of 4 quarters · filed 2016-03-10 |
| 2015-03-31 | $302.00K 10-Q · filed 2015-05-08 | $560.00K derived: sum of 2 quarters · filed 2016-03-10 | $795.00K derived: sum of 3 quarters · filed 2016-03-10 | $1.01M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-12-31 | $258.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $493.00K derived: sum of 2 quarters · filed 2016-03-10 | $708.00K derived: sum of 3 quarters · filed 2016-03-10 | $882.00K 10-K · filed 2016-03-10 |
| 2014-09-30 | $235.00K 10-Q · filed 2015-11-06 | $450.00K derived: sum of 2 quarters · filed 2015-11-06 | $624.00K 10-Q · filed 2015-11-06 | $685.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $215.00K 10-Q · filed 2015-08-07 | $389.00K 10-Q · filed 2015-08-07 | $450.00K derived: sum of 3 quarters · filed 2016-03-10 | $490.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $174.00K 10-Q · filed 2015-05-08 | $235.00K derived: sum of 2 quarters · filed 2016-03-10 | $275.00K derived: sum of 3 quarters · filed 2016-03-10 | $298.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $101.00K derived: sum of 2 quarters · filed 2016-03-10 | $124.00K derived: sum of 3 quarters · filed 2016-03-10 | $143.00K 10-K · filed 2016-03-10 |
| 2013-09-30 | $40.00K 10-Q · filed 2014-11-07 | $63.00K derived: sum of 2 quarters · filed 2014-11-07 | $82.00K 10-Q · filed 2014-11-07 | $102.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | $23.00K 10-Q · filed 2014-08-08 | $43.00K 10-Q · filed 2014-08-08 | $62.00K derived: sum of 3 quarters · filed 2015-03-13 | $86.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-03-31 | $20.00K 10-Q · filed 2014-05-12 | $39.00K derived: sum of 2 quarters · filed 2015-03-13 | $63.00K derived: sum of 3 quarters · filed 2015-03-13 | $111.00K derived: sum of 4 quarters · filed 2015-03-13 |
| 2012-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $43.00K derived: sum of 2 quarters · filed 2015-03-13 | $91.00K derived: sum of 3 quarters · filed 2015-03-13 | $91.00K 10-K · filed 2015-03-13 |
| 2012-09-30 | $24.00K 10-Q · filed 2013-11-12 | $72.00K derived: sum of 2 quarters · filed 2013-11-12 | $72.00K 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $48.00K 10-Q · filed 2013-08-09 | $48.00K 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |